{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:57:33Z","timestamp":1794477453723,"version":"4.9.1"},"reference-count":72,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research, Development and Innovation Office (Hungary)","award":["NKFI ANN-128524 (AL)"],"award-info":[{"award-number":["NKFI ANN-128524 (AL)"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Research, Development and Innovation Office (Hungary)","award":["K-135540 (JT)"],"award-info":[{"award-number":["K-135540 (JT)"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Similar to other malignancies, TCGA network efforts identified the detailed genomic picture of skin melanoma, laying down the basis of molecular classification. On the other hand, genome-wide association studies discovered the genetic background of the hereditary melanomas and the susceptibility genes. These genetic studies helped to fine-tune the differential diagnostics of malignant melanocytic lesions, using either FISH tests or the myPath gene expression signature. Although the original genomic studies on skin melanoma were mostly based on primary tumors, data started to accumulate on the genetic diversity of the progressing disease. The prognostication of skin melanoma is still based on staging but can be completed with gene expression analysis (DecisionDx). Meanwhile, this genetic knowledge base of skin melanoma did not turn to the expected wide array of target therapies, except the BRAF inhibitors. The major breakthrough of melanoma therapy was the introduction of immune checkpoint inhibitors, which showed outstanding efficacy in skin melanoma, probably due to their high immunogenicity. Unfortunately, beyond BRAF, KIT mutations and tumor mutation burden, no clinically validated predictive markers exist in melanoma, although several promising biomarkers have been described, such as the expression of immune-related genes or mutations in the IFN-signaling pathway. After the initial success of either target or immunotherapies, sooner or later, relapses occur in the majority of patients, due to various induced genetic alterations, the diagnosis of which could be developed to novel predictive genetic markers.<\/jats:p>","DOI":"10.3390\/ijms23105384","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T05:10:32Z","timestamp":1652332232000},"page":"5384","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction"],"prefix":"10.3390","volume":"23","author":[{"given":"J\u00f3zsef","family":"T\u00edm\u00e1r","sequence":"first","affiliation":[{"name":"2nd Department of Pathology, Semmelweis University, 1191 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9304-8473","authenticated-orcid":false,"given":"Andrea","family":"Lad\u00e1nyi","sequence":"additional","affiliation":[{"name":"Department of Surgical and Molecular Pathology and the National Tumor Biology Laboratory, National Institute of Oncology, 1122 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjd.15510","article-title":"The global burden of melanoma: Results from the Global Burden of Disease Study 2015","volume":"177","author":"Karimkhani","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10555-016-9613-5","article-title":"Genetic progression of malignant melanoma","volume":"35","author":"Doma","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/jid.2012.75","article-title":"Melanoma genetics: Recent findings take us beyond well-travelled pathways","volume":"132","author":"Law","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1375\/twin.11.2.183","article-title":"The Queensland Study of Melanoma: Environmental and genetic associations (Q-MEGA): Study design, baseline characteristics and repeatability of phenotypes and sun exposure measures","volume":"11","author":"Baxter","year":"2008","journal-title":"Twin Res. Hum. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1093\/hmg\/ddr415","article-title":"Genome-wide association study identifies novel loci predisposing to cutaneous melanoma","volume":"20","author":"Amos","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/ng.959","article-title":"Genome-wide association study identifies three new melanoma susceptibility loci","volume":"43","author":"Barrett","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_8","unstructured":"The Cancer Genome Atlas Network (2015). Genomic classification of cutaneous melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12253-019-00788-w","article-title":"KIT mutation incidence and pattern of melanoma in central-east Europe","volume":"26","author":"Doma","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1101\/gad.1437206","article-title":"Malignant melanoma: Genetics and therapeutics in the genomic era","volume":"20","author":"Chin","year":"2006","journal-title":"Genes Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.5213","article-title":"Melanoma subtypes: Genomic profiles, prognostic molecular markers and therapeutic possibilities","volume":"247","author":"Rabbie","year":"2019","journal-title":"J. Pathol."},{"key":"ref_12","unstructured":"Pfeffer, U. (2013). Chapter 2. Understanding Melanoma Progression by Gene Expression Signatures. Cancer Genomics, Springer."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.humpath.2013.02.007","article-title":"Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma","volume":"45","author":"Ordonez","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"642380","DOI":"10.3389\/fmed.2021.642380","article-title":"Molecular biomarkers for melanoma screening, diagnosis and prognosis: Current state and future directions","volume":"8","author":"Deacon","year":"2021","journal-title":"Front. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13000-015-0431-9","article-title":"A p16-ki-67-HMB45 immunohistochemistry score system as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"10","author":"Uguen","year":"2015","journal-title":"Diagn. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41379-018-0087-6","article-title":"Comparison of melanoma gene expression score with histopathology, FISH and SNP array for the classification of melanocytic neoplasms","volume":"31","author":"Reimann","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cncr.30385","article-title":"An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi","volume":"123","author":"Clarke","year":"2017","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/s41379-021-00870-2","article-title":"Histological regression in melanoma: Impact on sentinel lymph node status and survival","volume":"34","author":"Aivazian","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.semcancer.2019.08.011","article-title":"Immunologic and immunogenomic aspects of tumor progression","volume":"60","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/pcmr.12459","article-title":"The genomic landscape of cutaneous melanoma","volume":"29","author":"Zhang","year":"2016","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103374","DOI":"10.1016\/j.critrevonc.2021.103374","article-title":"TMB or not TMB as a biomarker: That is the question","volume":"163","author":"Addeo","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas","volume":"6","author":"Danaher","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000617","DOI":"10.1136\/jitc-2020-000617","article-title":"Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response","volume":"8","author":"Roelands","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Doma, V., K\u00e1rp\u00e1ti, S., R\u00e1s\u00f3, E., Barbai, T., and T\u00edm\u00e1r, J. (2019). Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5990-9"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Papp, O., Doma, V., Gil, J., Mark\u00f3-Varga, G., K\u00e1rp\u00e1ti, S., T\u00edm\u00e1r, J., and V\u00edzkeleti, L. (2021). Organ specific copy number variations in visceral metastases of human melanoma. Cancers, 13.","DOI":"10.3390\/cancers13235984"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Alkaraki, A., McArthur, G.A., Sheppard, K.E., and Smith, L.K. (2021). Metabolic plasticity in melanoma progression and response to oncogene targeted therapies. Cancers, 13.","DOI":"10.3390\/cancers13225810"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"18669","DOI":"10.1038\/srep18669","article-title":"Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers","volume":"6","author":"Nath","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_31","first-page":"44","article-title":"Prognostic biomarkers in melanoma: Tailoring treatments to patient","volume":"14","author":"Safai","year":"2021","journal-title":"J. Clin. Aenest. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Valenti, F., Falcone, I., Ungania, S., Desiderio, F., Giacomini, P., Bazzichetto, C., Conciatori, F., Gallo, E., Cognetti, F., and Ciliberto, G. (2021). Precision medicine and melanoma: Multi-omics approaches to monitoring the immunotherapy response. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083837"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11864-022-00948-2","article-title":"Promising blood-based biomarkers for melanoma: Recent progress of liquid biopsy and its future perspectives","volume":"23","author":"Kanemaru","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/PO.20.00119","article-title":"Long-term outcomes in a multicenter prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma","volume":"5","author":"Hsueh","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell\u2013inflamed tumor microenvironment in melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.7150\/thno.21471","article-title":"Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: Immunotherapeutic implications","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/0008-5472.CAN-16-2490","article-title":"Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment","volume":"77","author":"Varn","year":"2017","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/pcmr.12371","article-title":"Prognostic and predictive significance of immune cell infiltrating cutaneous melanoma","volume":"28","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Straker, R.J., Krupp, K., Sharon, C.E., Thaler, A.S., Kelly, N.J., Chu, E.Y., Elder, D.E., Xu, X., Miura, J.T., and Karakousis, G.C. (2022). Prognostic significance of primary tumor-infiltrating lymphocytes in a contemporary melanoma cohort. Ann. Surg. Oncol.","DOI":"10.1245\/s10434-022-11478-4"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2014.85","article-title":"Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II\u2013III resectable disease","volume":"134","author":"Sivendran","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1158\/1541-7786.MCR-18-0173","article-title":"A leukocyte infiltration score defined by a gene signature predicts melanoma patient prognosis","volume":"17","author":"Zhao","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/0008-5472.CAN-18-2864","article-title":"Genetic and environmental determinants of immune response to cutaneous melanoma","volume":"79","author":"Nsengimana","year":"2019","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"108069","DOI":"10.1016\/j.exer.2020.108069","article-title":"The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma","volume":"196","author":"Wang","year":"2020","journal-title":"Exp. Eye Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"710558","DOI":"10.3389\/fcell.2021.710558","article-title":"Construction and validation of a novel immunosignature for overall survival in uveal melanoma","volume":"9","author":"Gu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000334576","article-title":"Uveal melanoma: The inflammatory microenvironment","volume":"4","author":"Bronkhorst","year":"2012","journal-title":"J. Innate Immun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00262-020-02773-8","article-title":"Prognostic significance of PD-1\/PD-L1 expression in uveal melanoma: Correlation with tumor-infiltrating lymphocytes and clinicopathological parameters","volume":"70","author":"Singh","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy of melanoma: ASCO guideline","volume":"38","author":"Seth","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"110634","DOI":"10.1016\/j.celrep.2022.110634","article-title":"Melanomas with concurrent BRAF non-p600 and NF1 loss-of-function mutations are targetable by BRAF\/MEK inhibitor combination therapy","volume":"39","author":"Rajkumar","year":"2022","journal-title":"Cell Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10555-018-9729-x","article-title":"The role of lipid signaling in the progression of malignant melanoma","volume":"37","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for clinical benefit of immune checkpoint inhibitor treatment\u2014A review from the melanoma perspective","volume":"9","author":"Hassel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12253-018-0466-9","article-title":"Biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab","volume":"26","author":"Balatoni","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e000209","DOI":"10.1136\/jitc-2019-000209","article-title":"Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in melanoma patients","volume":"8","author":"Papp","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1610297","DOI":"10.3389\/pore.2022.1610297","article-title":"HLA class I downregulation in progressing metastases of melanoma patients treated with ipilimumab","volume":"28","author":"Hegyi","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-018-2131-2","article-title":"Defective HLA class I antigen processing machinery in cancer","volume":"67","author":"Cai","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.trecan.2021.07.006","article-title":"HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy","volume":"7","author":"Maggs","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T-cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.cell.2018.03.026","article-title":"Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade","volume":"173","author":"Shukla","year":"2018","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ng.3677","article-title":"Recurrent SerpinB3 and SerpinB4 mutations in patients who respond to anti-CTLA4 immunotherapy","volume":"48","author":"Riaz","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Lad\u00e1nyi, A., R\u00e1s\u00f3, E., Barbai, T., V\u00edzkeleti, L., Pusk\u00e1s, L.G., Kov\u00e1cs, S., Gy\u0151rffy, B., and T\u00edm\u00e1r, J. (2022). Identification of a tumor cell associated type I IFN resistance gene expression signature of human melanoma, the components of which have a predictive potential for immunotherapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052704"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5384\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:33Z","timestamp":1760137773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23105384"],"URL":"https:\/\/doi.org\/10.3390\/ijms23105384","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]}}}